Wu, Fei <br/><br/>
Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.  [electronic resource] 

 -  Cancer letters  01 2017 
 - 207-214 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2016.10.021  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Carbamates--pharmacology<br/>Cdc20 Proteins--antagonists & inhibitors<br/>Cullin Proteins--antagonists & inhibitors<br/>Cyclopentanes--pharmacology<br/>Diamines--pharmacology<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm<br/>Enzyme Inhibitors--pharmacology<br/>HeLa Cells<br/>Humans<br/>Male<br/>Molecular Targeted Therapy<br/>Mutation<br/>Nuclear Proteins--genetics<br/>Prostatic Neoplasms--drug therapy<br/>Protein Interaction Domains and Motifs<br/>Proteolysis<br/>Pyrimidines--pharmacology<br/>Repressor Proteins--genetics<br/>Time Factors<br/>Transfection<br/>Ubiquitination